Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.
作者信息
Miners John O, Polasek Thomas M
机构信息
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.
出版信息
Clin Pharmacol Ther. 2025 Aug;118(2):301-303. doi: 10.1002/cpt.3734. Epub 2025 May 26.
Abstract
摘要
相似文献
1
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.基于胆红素肝脏摄取和葡萄糖醛酸化体外动力学的生理药代动力学模型的注意事项：对董等人的评论
Clin Pharmacol Ther. 2025 Aug;118(2):301-303. doi: 10.1002/cpt.3734. Epub 2025 May 26.
2
First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics.基于自由药物假说、白蛋白促进肝摄取或动态结合动力学的分数未结合模型预测具有搅拌池模型的药物在人体内的肝清除率：模型比较评估。
J Pharm Sci. 2024 Aug;113(8):2641-2650. doi: 10.1016/j.xphs.2024.05.021. Epub 2024 May 24.
3
species on palms - integrative taxonomic approach for species boundaries delimitation in the genus , with the description of .棕榈树上的物种——该属物种界限划分的综合分类学方法，以及对……的描述 。 （原文中“with the description of.”后面内容缺失，翻译可能不太完整准确）
Stud Mycol. 2024 Dec;109:487-594. doi: 10.3114/sim.2024.109.08. Epub 2024 Oct 23.
4
Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.通过整合体外数据，采用生理药代动力学（PBPK）模型对维卡西纳宾进行前瞻性药物相互作用风险评估。
Clin Pharmacol Ther. 2025 Aug;118(2):428-437. doi: 10.1002/cpt.3686. Epub 2025 Apr 28.
5
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization.基于生理的药代动力学（PBPK）模型的进展及其在支持口服药物产品开发与协调方面的监管效用。
Pharm Res. 2025 Mar 28. doi: 10.1007/s11095-025-03849-9.
6
Physiologically-based pharmacokinetic modeling of rosuvastatin in Chinese: Predicting the impact of SLCO1B1 and ABCG2 genetic variants and hepatic impairment on drug exposure.瑞舒伐他汀在中国人群中的生理药代动力学建模：预测SLCO1B1和ABCG2基因变异及肝损伤对药物暴露的影响。
J Pharm Sci. 2025 Aug;114(8):103866. doi: 10.1016/j.xphs.2025.103866. Epub 2025 Jun 7.
7
First Report of causing leaf spot on in China.关于在中国引起叶斑病的首次报道。 （原英文文本表述不太完整准确，推测完整意思大概如此）
Plant Dis. 2025 Jun 27. doi: 10.1094/PDIS-05-25-0972-PDN.
8
Optimizing Extended-release Formulation of l-tetrahydropalmatine Based on In Vivo Outcomes Using Integrated Modeling Approaches.基于体内结果运用整合建模方法优化左旋四氢巴马汀缓释制剂
AAPS PharmSciTech. 2025 Jun 26;26(6):170. doi: 10.1208/s12249-025-03165-w.
9
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment.药物相互作用的生理药代动力学（PBPK）建模：文献综述揭示，作为可信度评估的一部分，需要加强对模型输入和输出的验证。
Clin Transl Sci. 2025 Jul;18(7):e70299. doi: 10.1111/cts.70299.
10
Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.多尺度计算建模助力放射性药物治疗疗效最大化并最小化副作用：氨基酸输注建模
PLoS Comput Biol. 2025 Jul 16;21(7):e1013247. doi: 10.1371/journal.pcbi.1013247.
本文引用的文献
1
Physiologically based pharmacokinetic modeling of small molecules: How much progress have we made?小分子的基于生理的药代动力学建模：我们取得了多大进展？
Drug Metab Dispos. 2025 Jan;53(1):100013. doi: 10.1124/dmd.123.000960. Epub 2024 Nov 22.
2
Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration.阿扎那韦给药后胆红素升高的主要原因可能是OATP1B1/3受到抑制，而非UGT1A1受到抑制。
Clin Pharmacol Ther. 2025 Aug;118(2):497-509. doi: 10.1002/cpt.3529. Epub 2024 Dec 14.
3
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards.通过细胞色素P450对竞争性抑制性代谢药物-药物相互作用的静态与动态模型预测：前进一步，后退两步。
Clin Pharmacokinet. 2025 Jan;64(1):155-170. doi: 10.1007/s40262-024-01457-1. Epub 2024 Dec 10.
4
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.药物-药物相互作用改变葡萄糖醛酸化药物的暴露：范围、尿苷二磷酸葡萄糖醛酸转移酶（UGT）酶选择性、机制（抑制和诱导）以及临床意义。
Pharmacol Ther. 2023 Aug;248:108459. doi: 10.1016/j.pharmthera.2023.108459. Epub 2023 May 30.
5
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.用于体外人药物和化学物质葡萄糖醛酸化表征及尿苷二磷酸葡萄糖醛酸基转移酶反应表型分析的循证策略。
Pharmacol Ther. 2021 Feb;218:107689. doi: 10.1016/j.pharmthera.2020.107689. Epub 2020 Sep 25.
6
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.拉帕替尼、帕唑帕尼、瑞戈非尼和索拉非尼对人尿苷二磷酸葡萄糖醛酸转移酶的抑制作用：与高胆红素血症的关系。
Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.
7
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.重新审视胆红素葡萄糖醛酸化：使用重组 UGT1A1 估计酶动力学的适当测定条件。
Drug Metab Dispos. 2010 Nov;38(11):1907-11. doi: 10.1124/dmd.110.033829. Epub 2010 Jul 28.
8
Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism.对经UGT1A1*28多态性基因分型的人肝微粒体的UDP葡萄糖醛酸基转移酶活性的表征。
Drug Metab Dispos. 2007 Dec;35(12):2270-80. doi: 10.1124/dmd.107.017806. Epub 2007 Sep 26.
9
Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin.有机阴离子转运多肽OATP - A、OATP - C和OATP - 8在胎儿胆红素经人胎盘 - 母体肝脏串联排泄途径中的作用。
Biochem J. 2003 May 1;371(Pt 3):897-905. doi: 10.1042/BJ20030034.
10
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.人有机阴离子转运体SLC21A6对胆红素及其结合物的肝脏摄取。
J Biol Chem. 2001 Mar 30;276(13):9626-30. doi: 10.1074/jbc.M004968200. Epub 2000 Dec 27.
Zotero 插件